Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.
Condition: Lyme Borreliosis Interventions: Biological: VLA15; Biological: Placebo Sponsor: Valneva Austria GmbH Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials